Free Access
Med Sci (Paris)
Volume 23, Number 4, Avril 2007
Page(s) 391 - 398
Section M/S revues
Published online 15 April 2007
  1. Teng TO, Adams ME, Pliskin JS, et al. Five-hundred life-saving interventions and their cost-effectiveness. Risk Analysis 1995; 15 : 369–90. [Google Scholar]
  2. Chen RT, Orenstein WA. Epidemiologic methods in immunization programs. Epidemiol Rev 1996; 18 : 99–117. [Google Scholar]
  3. Nokes DJ, Anderson RM. Vaccine safety versus vaccine efficacy in mass immunisation programs. Lancet 1991; 338 : 1309–12. [Google Scholar]
  4. Jefferson T, Demicheli V, Pratt M. Evidence-based vaccinology: the work of the Cochrane vaccine field. J Epidemiol Community Health 1998; 52 : 207–8. [Google Scholar]
  5. Dittmann S. Vaccine safety: risk communication: a global perspective. Vaccine 2001; 19 : 2446–56. [Google Scholar]
  6. André F. Vaccination contre la varicelle. In : Vaccinations, actualités et perspectives. Expertise collective de l’Inserm. Paris : Éditions Inserm, 1999. [Google Scholar]
  7. Anderson RM, Donnelly CA, Gupta S. Vaccine design, evaluation, and community-based use for antigenically variable infectious agents. Lancet 1997; 350 : 1466–70. [Google Scholar]
  8. ACIP, CDC. Prevention of varicella: recommendations of the advisory committee on immunization practices (ACIP). Centers for Disease Control and Prevention. MMWR Morb Mortal Wkly Rep 1996; 45 (RR-11) : 1–36. [Google Scholar]
  9. Vázquez M, LaRussa PS, Gershon AA, et al. Effectiveness over time of varicella vaccine. JAMA 2004; 291 : 851–5. [Google Scholar]
  10. Boelle PY. Épidémiologie théorique et vaccination. Rev Med Interne 2007 (sous presse). [Google Scholar]
  11. Halloran ME. Epidemiologic effects of varicella vaccination. Infect Dis Clin North Am 1996; 10 : 631–55. [Google Scholar]
  12. Bonmarin I, Levy-Bruhl D. La rougeole en France : impact épidémiologique d’une couverture vaccinale sub-optimale. Eurosurveillance 2002; 7 : 55–60. [Google Scholar]
  13. Seward JF, Watson BM, Peterson CL, et al. Varicella disease after introduction of varicella vaccine in the United States, 1995-2000. JAMA 2002; 287 : 606–11. [Google Scholar]
  14. Zhou F, Harpaz R, Jumaan AO, et al. Impact of varicella vaccination on health care utilization. JAMA 2005; 294 : 797–802. [Google Scholar]
  15. Nguyen HQ, Jumaan AO, Seward JF. Decline in mortality due to varicella after implementation of varicella vaccination in the United States. N Engl J Med 2005; 352 : 450–8. [Google Scholar]
  16. Anderson RM, Donnelly CA, Gupta S. Vaccine design, evaluation, and community-based use for antigenically variable infectious agents. Lancet 1997; 350 : 1466–70. [Google Scholar]
  17. Levine MM, Levine OS. Influence of disease burden, public perception, and other factors on new vaccine development, implementation, and continued use. Lancet 1997; 350 : 1386–92. [Google Scholar]
  18. Zimmerman RK, Schlesselman JJ, Mieczkowski TA, et al. Physician concern about vaccine adverse effects and potential litigation. Arch Pediatr Adolesc Med 1998; 152 : 12–9. [Google Scholar]
  19. Comité Technique des Vaccinations, Direction Générale de la santé. Guide des vaccinations. Paris : Comité français d’éducation pour la santé (CFES), 2006. [Google Scholar]
  20. Bonmarin I, Ndiaye B, Seringe E, Levy-Brühl D. Épidémiologie de la varicelle en France. BEH 2005; 2005 : 30–2. [Google Scholar]
  21. Boëlle PY, Hanslik T. Varicella in non-immune persons: incidence, hospitalization and mortality rates. Epidemiol Infect 2002; 129 : 599–606. [Google Scholar]
  22. Hanslik T, Boëlle PY, Schwarzinger M, et al. Varicella in French adolescents and adults: individual risk assessment and cost-effectiveness of routine vaccination. Vaccine 2003; 21 : 3614–22. [Google Scholar]
  23. Chen RT, DeStefano F. Vaccine adverse events: causal or coincidental ? Lancet 1998; 351 : 611–2. [Google Scholar]
  24. Loupi E, Baudard S, Debois H, Pignato F. Les risques associés aux vaccinations. Ann Med Interne 1998; 149 : 361–71. [Google Scholar]
  25. Gershon AA, M. Takahashi, Seward J. Vaccines, 4th ed. In : Plotkin SA, Orenstein WA, eds. Philadelphia : Saunders, 2004 : 783–824. [Google Scholar]
  26. Hambleton S, Gershon AA. Preventing varicella-zoster disease. Clin Microbiol Rev 2005; 18 : 70–80. [Google Scholar]
  27. Tsolia M, Gershon AA, Steinberg SP, Gelb L. Live attenuated varicella vaccine: evidence that the virus is attenuated and the importance of skin lesions in transmission of varicella-zoster virus. J Pediatr 1990; 116 : 184–9. [Google Scholar]
  28. Jumaan AO, Yu O, Jackson LA, et al. Incidence of herpes zoster, before and after varicella-vaccination-associated decreases in the incidence of varicella, 1992-2002. J Infect Dis 2005; 191 : 2002–7. [Google Scholar]
  29. Ellenberg SS, Chen RT. The complicated task of monitoring vaccine safety. Public Health Reports 1997; 112 : 10–20. [Google Scholar]
  30. Singleton JA, Lloyd JC, Mootrey GT, et al. VAERS Working Group. An overview of the vaccine adverse event rporting system (VAERS) as a surveillance system. Vaccine 1999; 17 : 2908–17. [Google Scholar]
  31. Braun MM, Ellenberg SS. Descriptive epidemiology of advserse events after immunization: reports of the vaccine adverse event reporting system, 1991-1994. J Pediatr 1997; 131 : 529–35. [Google Scholar]
  32. Sharrar RG, LaRussa P, Galea SA, et al. The postmarketing safety profile of varicella vaccine. Vaccine 2000; 19 : 916–23. [Google Scholar]
  33. Gershon AA. Varicella vaccine: rare serious problems-but the benefits still outweigh the risks. J Infect Dis 2003; 188 : 945–7. [Google Scholar]
  34. Wise RP, Salive ME, Braun MM, et al. Postlicensure safety surveillance for varicella vaccine. JAMA 2000; 284 : 1271–9. [Google Scholar]
  35. Levin MJ, Dahl KM, Weinberg A, et al. Development of resistance to aciclovir during chronic infection with the Oka vaccine strain of varicella-zoster virus, in an immunosuppressed child. J Infect Dis 2003; 188 : 954–9. [Google Scholar]
  36. Hanslik T, Blanchon T, Alvarez Fabián P. Vaccination des adultes contre la varicelle et le zona. Rev Med Interne 2007 (sous presse). [Google Scholar]
  37. Valleron AJ. Mise en évidence des faits et recherche des causes en épidémiologie environnementale : enjeux méthodologiques. CR Acad Sci Paris SerIII 2000; 323 : 617–28. [Google Scholar]
  38. Hill AB. The environment and disease: association or causation ? Proc R Soc Med 1965; 58 : 295–300. [Google Scholar]
  39. Kramer MS. Difficulties in assessing the advserse effects of drugs. Br J Clin Pharmacol 1981; 11 (suppl 1) : S105–10. [Google Scholar]
  40. Institute of Medicine. Causality and evidence. In : Stratton KR, Howe CJ, Johnston RB, eds. Adverse events associated with childhood vaccine, evidence bearing on causality. Washington DC : National Academy Press, 1994 : 19–33. [Google Scholar]
  41. World Health Organization. Causality assessement of adverse events following immunization. Wkly Epidemiol Rec 2001; 76 : 85–92. [Google Scholar]
  42. Collet JP, MacDonald N, Cashman N, Pless R, Advisory committee in causality assessment. Monitoring signals for vaccine safety: the assessment of individual adverse event report by an expert advisory committee. Bull World Health Org 2000; 78 : 178–85. [Google Scholar]
  43. Chauvin P, Valleron AJ. Persistence of susceptibility to measles in France despite routine immunization: a cohort analysis. Am J Publ Health 1999, 89 : 79–81. [Google Scholar]
  44. Levy-Bruhl D, Desenclos JC, Rebiere I, Drucker J. Central demyelinating disorders and hepatitis B vaccination: a risk-benefit approach for pre-adolescent vaccination in France. Vaccine 2002; 20 : 2065–71. [Google Scholar]
  45. Conseil Supérieur d’Hygiène Publique de France. Calendrier vaccinal 2006. BEH 2006; n° 2 : 211–6. [Google Scholar]
  46. Devey ME, Bleasdale K, Isenberg DA. Antibody affinity and IgG subclass of responses to tetanus toxoid in patients with rheumatoid arthritis and systemic lupus erythematosus. Clin Exp Immunol 1987; 68 : 562–9. [Google Scholar]
  47. Mitchell DM, Fitzharris P, Knight RA, et al. Kinetics of specific anti-influenza antibody production by cultured lymphocytes from patients with systemic lupus erythematosus following influenza immunization. Clin Exp Immunol 1982; 49 : 290–6. [Google Scholar]
  48. Turner-Stokes L, Cambridge G, Corcoran T, et al. In vitro response to inluenza immunisation by peripheral blood mononuclear cells from patients with systemic lupus erythematosus and other autoimmune diseases. Ann Rheum Dis 1988; 47 : 532–5. [Google Scholar]
  49. McDonald E, Jarret MP, Schiffman G, Grayzel AI. Persistence of pneumococcal antibodies after immunization in patients with systemic lupus erythematosus. J Rheumatol 1984; 11 : 306–8. [Google Scholar]
  50. Ioannou Y, Isenberg DA. Immunisation of patients with systemic lupus erythematosus: the current state of play. Lupus 1999; 8 : 497–501. [Google Scholar]
  51. Hanslik T, Wechsler B, Vaillant JN, et al. A survey of physicians’ vaccine risk perception and immunization practices for subjects with immunological diseases. Vaccine 2000; 19 : 908–15. [Google Scholar]
  52. Chen RT. Vaccine risks: real, perceived and unknown. Vaccine 1999; 17 : S41–6. [Google Scholar]
  53. Slovic P. Perception of risk. Science 1987; 236 : 280–5. [Google Scholar]
  54. Analyse économique. In : Vaccinations, actualités et perspectives. Expertise collective de l’Inserm. Paris : Éditions Inserm, 1999 : 103–23. [Google Scholar]
  55. Teng TO, Adams ME, Pliskin JS, et al. Five-hundred life-saving interventions and their cost-effectiveness. Risk Analysis 1995; 15 : 369–90. [Google Scholar]
  56. Mark DB, Hlatky MA, Califf RM, et al. Cost-effectiveness of thrombotic therapy with tissue plasminogen activator as compared with streptokinase in acute myocardial infarction. N Engl J Med 1995; 332 : 1418–24. [Google Scholar]
  57. Lieu TA, Cochi SL, Black SB, et al. Cost-effectiveness of a routine varicella vaccination program for US children. JAMA 1994; 271 : 375–81. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.